HHS Earnings

HHS reported its earnings on 2025-05-08, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a -7.47% price change on the earnings day and a -4.35% change over the next five days, reflecting market reactions to the results.

Following HHS's earnings announcement on 2025-05-08, the stock price moved by -7.47% on the day of the release. Over the subsequent five days, it saw a -4.35% change. Historically, HHS's stock price tends to shift by an average of -0.99% in the 10 days leading up to earnings and -2.21% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate HHS's annual revenue to reach 51.70M, while the EPS is projected at 0.41. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between HHS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, HHS's stock price typically moves by -0.99% in the 10 days before its earnings and -2.21% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of 0.41 and revenue of 51.70M.

The earnings call presents mixed results. The slight revenue increase and strategic initiatives like Project Elevate and sales team expansion show potential. However, the anticipated revenue decline in Q4, increased operating expenses, decreased operating income, and lack of shareholder returns weigh negatively. The negative sentiment is compounded by substantial cash outflow due to pension plan termination and economic pressures affecting revenue growth. The Q&A session did not provide additional insights to alter this view. Overall, the company's financial health and guidance suggest a negative stock price reaction.